Share

Canagliflozin Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease

Late-breaking exploratory analysis from the CANVAS Program presented at the American College of Cardiology’s 67th Annual Scientific Session The results of  recent analysis showed that canagliflozin significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk. This exploratory analysis from...
Share

Reduced Time in Hypoglycemia Demonstrated in Recent Insulin Pump Trial

Positive results were announced this week from the study of a new insulin pump with a predictive low glucose suspend (PLGS) feature. Data showed that the system achieved the primary outcome of reducing time spent in hypoglycemia compared to sensor-augmented pump therapy alone. The company developing the device, Tandem Diabetes Care, is marketing its new...
Share

FDA Approves Semaglutide Injection For the Treatment of Adults with Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) approved semaglutidea once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The drug, produced by Novo Nordisk and marketed as OZEMPIC®, is administered once weekly, on the same day each week, and can be taken...
Share

Crossing Borders: The Impact of the Travel Ban

Al_Nofal_Alaa_MUG_RGB [UPDATE: Since this story went to print, the Trump administration has issued a new travel ban that places restrictions on immigrants from Chad, Iran, Libya, North Korea, Somalia, Syria, Venezuela, and Yemen. Therefore, the Supreme Court postponed oral arguments in the travel ban case that were scheduled for October.] While the ACA repeal effort is ongoing...
Share

Study Shows People with Type 2 Diabetes Benefit from Continuous Glucose Monitoring

The results show that continuous glucose monitoring is an effective diabetes management tool that could benefit millions of people with type 2 diabetes on insulin therapy People with type 2 diabetes on a multiple daily injection (MDI) insulin therapy benefit from the use of continuous glucose monitoring (CGM), according to a study recently published in...
Share

Lab Improvement: A Few Tips to Upgrading Your Lab

As technology evolves and tech staff expands and contracts, it’s key to have a laboratory environment that evolves as well. If you’re looking to give your lab space an upgrade, Endocrine News has a few helpful hints. It is not uncommon to outgrow your laboratory space. A new work function may change your equipment needs,...
Share

Researchers Studying Novel Gestational Diabetes Screening Alternative

Researchers at Brigham and Women’s Hospital (BWH) recently published a study demonstrating the potential clinical utility of glycated CD59 (GCD59) as a novel biomarker for the screening and diagnosis of gestational diabetes mellitus (GDM). The data from this study showed that a single blood test that measures plasma GCD59 at week 24-28 of gestation identified...
Show More